Sectors
KURA
Kura Oncology, Inc.
12.65
2 x 9.15
2 x 16.38
bid
ask
-
0.01
0.08%
2 @ 07:30 PM
12.75 +0.10 (0.76%)
| Ytd | 21.75% | |
| 1y | 60.13% |
12.53
day range
12.76
7.36
52 week range
13.90
| Open | 12.71 | Prev Close | 12.66 | Low | 12.53 | High | 12.76 | Mkt Cap | 1.13B |
| Vol | 1.96M | Avg Vol | 1.84M | EPS | -3.37 | P/E | N/A | Forward P/E | -5.62 |
| Beta | 0.38 | Short Ratio | 10.03 | Inst. Own | 99.62% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-03 | 50-d Avg | 10.84 | 200-d Avg | 9.75 | 1yr Est | 32.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-03 | 2026-09 | -0.84 | N/A | N/A | N/A |
| 2026-08-12 | 2026-06 | -0.88 | -0.77 | 0.11 | 12.23% |
| 2026-05-12 | 2026-03 | -0.88 | -0.83 | 0.05 | 5.68% |
| 2026-03-05 | 2025-12 | -0.72 | -0.92 | -0.2 | -27.78% |
| 2025-11-04 | 2025-09 | -0.57 | -0.85 | -0.28 | -49.12% |
| 2025-08-07 | 2025-06 | 0.15 | -0.75 | -0.9 | -600.00% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-24 | Citizens | Upgrade | Market Outperform | Market Outperform |
| 2026-08-13 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-07-28 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-06-15 | Citizens | Upgrade | Market Outperform | Market Outperform |
| 2026-04-14 | Lake Street | Upgrade | Buy | |
| 2026-03-24 | Mizuho | Upgrade | Outperform | Outperform |
Profile
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-08-18 | BAIR TERESA BROPHY | Officer | 195.44K | Sale |
| 2026-01-26 | BURROWS FRANCIS J. PH.D. | Officer | 32.42K | Sale |
| 2026-01-26 | DOYLE THOMAS JAMES | Officer | 145.67K | Sale |
| 2026-05-18 | FORD KATHLEEN | Chief Operating Officer | 153.56K | Sale |
| 2025-12-08 | HASNAIN FAHEEM | Director | 23.98K | Sale |
| 2026-06-17 | LEONI MOLLIE M.D. | Officer | 182.35K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Blackrock Inc. | 10.51M | 132.94M | 11.81% |
| 2026-06-29 | Montanova Capital LLC | 8.58M | 108.48M | 9.64% |
| 2026-06-29 | BVF Inc. | 8.45M | 106.84M | 9.49% |
| 2026-06-29 | State Street Corporation | 5.33M | 67.41M | 5.99% |
| 2026-06-29 | Vanguard Capital Management LLC | 3.92M | 49.54M | 4.40% |
| 2026-06-29 | Armistice Capital, LLC | 3.68M | 46.53M | 4.13% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 3.09M | 39.14M | 3.48% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.73M | 34.49M | 3.07% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 2.21M | 27.96M | 2.48% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 974.77K | 12.33M | 1.10% |
| 2026-05-30 | Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 804.82K | 10.18M | 0.90% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 Growth ETF | 785.10K | 9.93M | 0.88% |